This is a working overview of Bremelanotide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-21 and is reviewed periodically as new material appears.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic analogue of alpha-MSH |
| Molecular formula | C50H68N14O10 | Acetate salt form commonly reported |
| Molecular mass | ~1025 Da | Monoisotopic value near 1025.2 |
| Key structural motif | Lactam bridge | Asp side chain to Lys side chain |
| Solid appearance | White to off-white powder | Lyophilised and hygroscopic |
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
60. Vopr Onkol. 2001;47(5):601-7. [Effect of vilon and epithalone on induction and growth of induced bladder neoplasms in rats]. [Article in Russian] Pliss GB(1), Mel'nikov AS, Malinin VV, Khavinson VKh. Author information: (1)N.N. Petrov Research Institute of Oncology, Ministry of Health of the RF, St. Petersburg. Experimental data on the effect of peptides--Vilon (Lys-Glu) and Epitalon (Ala-Glu-Asp-Gly)--on induction of urinary bladder tumors in rats are presented. Treatment with Vilon was followed by a significant fall in tumor incidence in 56% of experimental animals, as compared with 75.5% in control, as well as inhibition of early-onset neoplastic changes in the bladder mucosa. No inhibitory effect of Epitalon was recorded.
Uranium-233 (233U or U-233) is a fissile isotope of uranium that is bred from thorium-232 as part of the thorium fuel cycle. Uranium-233 was investigated for use in nuclear weapons and as a reactor fuel. It has been used successfully in experimental nuclear reactors and has been proposed for much wider use as a nuclear fuel. It decays primarily by alpha emission, with a half-life of about 159,200 years, and is part of the neptunium decay chain. Uranium-233 is produced by the neutron irradiation of thorium-232. When thorium-232 absorbs a neutron, it becomes thorium-233, which has a half-life of about 22 minutes. Thorium-233 decays into protactinium-233 through beta decay. Protactinium-233 has a longer half-life of about 27 days to further decay into uranium-233; some proposed molten salt reactor designs attempt to physically isolate the protactinium from further neutron capture before beta decay can occur, to maintain the neutron economy. 233U usually fissions on neutron absorption, but sometimes retains the neutron, becoming uranium-234. At a neutron energy of 0.0253 eV, JENDL-4.0 data give capture-to-fission ratios of about 0.085 for uranium-233, 0.169 for uranium-235 and 0.363 for plutonium-239.
There have been a significant number of publications since then, and a Food and Drug Administration panel voted, with some controversy, 20:3 that available studies "supported a signal of harm", but voted 22:1 to keep the drug on the market. The meta-analysis was not supported by an interim analysis of the trial designed to evaluate the issue, and several other reports have failed to conclude the controversy. This weak evidence for adverse effects has reduced the use of rosiglitazone, despite its important and sustained effects on glycemic control. Safety studies are continuing. In contrast, at least one large prospective study, PROactive 05, has shown that pioglitazone may decrease the overall incidence of cardiac events in people with type 2 diabetes who have already had a heart attack.
Acanthaster planci, starfish (2014) Apostichopus japonicus, sea cucumber (2017) Arbacia lixula, black sea urchin (2024) Astropecten irregularis, sand sea star (2024) Australostichopus mollis, Australian sea cucumber (2016) Chiridota hydrothermica, deep sea cucumber (2024) Diadema setosum, Long-spined sea urchin (2024) Echinometra lucunter, rock boring urchin (2023) Ophionereis fasciata, mottled brittlestar (2016) Patiriella regularis, the New Zealand common cushion star (2016) Plazaster borealis, Octopus starfish (2022) Strongylocentrotus purpuratus, a sea urchin and model deuterostome (2006)
Common techniques used by hematology analyzers to identify cells include light scattering, Coulter counting, and cytochemical staining techniques. Some analyzers also use radiofrequency analysis and monoclonal antibody tagging to identify cells. Staining techniques used in differential analyzers include staining of myeloperoxidase, an enzyme found in cells of myeloid lineage, and nucleic acids, which are found in higher concentrations in immature cells. A small volume of blood (as low as 150 microlitres) is aspirated into the analyzer, where reagents are applied to lyse red blood cells and preserve white blood cells. The sample is diluted and passed into a flow cell, which uses hydrodynamic focusing to isolate single cells for accurate analysis of their properties. Various cellular parameters, such as size, complexity and staining reactions, are measured and analyzed to identify cell populations. Basophils are often quantified using a reagent that lyses the cytoplasm of other white blood cells but leaves basophils intact. Samples that have abnormal results or are suspected to contain abnormal cells are flagged by the analyzer for manual blood smear review. To ensure that results from the automated analyzer are correct, quality control samples are run at least once per day. These are samples with known results that are most often provided by the instrument manufacturer. Laboratories compare their differential results to the known values to ensure the instrument is operating correctly.
Sources: pubmed.ncbi.nlm.nih.gov
Further, chemical biology employs biological systems to create non-natural hybrids between biomolecules and synthetic devices (for example, emptied viral capsids that can deliver gene therapy or drug molecules).
Opium production has led to rising tensions in Afghan villages. Though direct conflict has yet to occur, the opinions of the new class of young rich men involved in the opium trade are at odds with those of the traditional village leaders.
=== Pregnancy and breastfeeding === If needed in pregnancy, adequate human studies are lacking, therefore the drug should be given in pregnant women only if clearly indicated. It may cause hypotonia in the newborn if given closely before delivery.
== Neurotoxicity == BMAA can cross the blood–brain barrier in rats. It takes longer to get into the brain than into other organs, but once there, it is trapped in proteins, forming a reservoir for slow release over time.
Sources: en.wikipedia.org
The four substrates of this enzyme are 7-methylxanthine, reduced nicotinamide adenine dinucleotide (NADH), oxygen, and a proton. Its products are xanthine, oxidised NAD+, water, and formaldehyde. The enzyme is a non-heme iron protein that is part of the pathway of caffeine degradation in Pseudomonas putida.
=== NT-501 === NT-501 is a product being developed by Neurotech that consists of encapsulated human cells genetically modified to secrete ciliary neurotrophic factor (CNTF). In a clinical trial, NT-501 demonstrated a statistically significant reduction of photoreceptor degradation in patients with retinitis pigmentosa.
During the 1982–83 event, jack mackerel and anchoveta populations were reduced, scallops increased in warmer water, but hake followed cooler water down the continental slope, while shrimp and sardines moved southward, so some catches decreased while others increased. Horse mackerel have increased in the region during warm events. Shifting locations and types of fish due to changing conditions create challenges for the fishing industry. Peruvian sardines have moved during El Niño events to Chilean areas. Other conditions provide further complications, such as the government of Chile in 1991 creating restrictions on the fishing areas for self-employed fishermen and industrial fleets. Southern Brazil and northern Argentina also experience wetter than normal conditions during El Niño years, but mainly during the spring and early summer. Central Chile receives a mild winter with large rainfall, and the Peruvian-Bolivian Altiplano receives more precipitation during its rainy season, sometimes being exposed to unusual winter snowfall events. Drier and hotter weather occurs in parts of the Amazon River Basin, Colombia, and Central America. During a time of La Niña, drought affects the coastal regions of Peru and Chile. From December to February, northern Brazil is wetter than normal. La Niña causes higher than normal rainfall in the central Andes, which in turn causes catastrophic flooding on the Llanos de Mojos of Beni Department, Bolivia. Such flooding is documented from 1853, 1865, 1872, 1873, 1886, 1895, 1896, 1907, 1921, 1928, 1929 and 1931.
Sources: en.wikipedia.org
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.
The two compounds share the same cyclic core and are both non-selective melanocortin agonists. They differ chiefly at the C-terminus, where bremelanotide carries a free carboxylic acid and melanotan II a terminal amide.
Receptor binding profiles are well characterised in vitro, but the downstream pathway linking MC4R activation to behavioural effects is not fully mapped. Several intermediate neural circuits have been proposed without definitive confirmation.
MC4R is regarded as the primary mediator on the basis of binding and functional assays. Other subtypes are also engaged, which helps explain flushing and related side effects. The step from receptor activation to reported desire change remains partly inferential.